ClinicalTrials.gg
RecruitingNCT07093554Updated Jan 5, 2026

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

A Phase 1 interventional study of Talquetamab and Ciltacabtagene Autoleucel in Relapse Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Medical College of Wisconsin · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies testing talquetamab in Multiple Myeloma — 20 open to participants now, 27 under way, 6 of them phase 3. talquetamab · Multiple Myeloma.

Planned enrollment
21st of 30
31 · median 50
Started
2025
with 6 others
Phase 1
6 of 30
4 open now
Primary completion
2027-07
later than 7 of 26 live
Registered
25th of 30
by date
Lead sponsor
1 of 30
Medical College of Wisconsin

Among the 30 studies testing talquetamab in Multiple Myeloma, this one is the 21st largest by planned enrollment, is one of 7 that started in 2025, is one of 6 in phase 1, reaches primary completion later than 7 of the 26 other live ones, and was the 25th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

20 of the 30 studies testing talquetamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About talquetamab

talquetamab: first FDA approval 2023 (TALVEY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing talquetamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

Read the detailed description

This study will enroll patients with RRMM who have received at least one prior line of therapy and are eligible for both commercial talquetamab and cilta-cel. Patients will enroll prior to apheresis. Following apheresis, patients will receive one cycle of talquetamab therapy. An additional cycle of talquetamab will be allowed if manufacturing delays result in an expected lymphodepletion date > 4 weeks from the last full dose of talquetamab in Cycle 1. Following successful manufacturing, patients will receive lymphodepleting chemotherapy and cilta-cel infusion.

03

Conditions studied

  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma

Browse trials for

Keywords

  • Bispecific Antibody
  • CAR-T therapy
  • Refractory Multiple Myeloma
  • Relapse Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years.
  2. confirmed diagnosis of multiple myeloma with evidence of progressive disease as defined by the IMWG criteria.
  3. Have , defined as:

    1. Serum M-protein level ≥ 1.0 g/dL, or
    2. Urine M-protein level ≥ 200 mg/24 hours, or
    3. In patients without a measurable M-protein, an involved light chain level ≥ 10 mg/dL and an abnormal free light chain ratio.
  4. Patient had at least one (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).
  5. Patient meets the requirements for the use of talquetamab, as per the most recent FDA prescription information.
  6. Patient plans to receive cilta-cel and meets the criteria for commercial use as per the most recent FDA prescription information.
  7. Have an (ECOG) performance status of 0-2 at screening.
  8. Have the following clinical laboratory values at screening:

    Adequate bone marrow function:

    * ≥ 8.0 g/dL; * ≥ 1,000/mcL; Absolute Lymphocyte Count* ≥ 200/mcL; * ≥ 25,000/mm\^3

    *Transfusion and growth factor support within 72 hours allowed.

    Adequate hepatic function:

    Total \< 2 mg/dL; (Serum Glutamic Oxaloacetic Transaminase)/Alanine Aminotransferase \< 5 times institutional upper limit

    Adequate renal function:

    ≥ 30 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal

  9. Female patients must meet one of the following:

    1. for at least one year before the screening visit, or
    2. Surgically sterile, or
    3. If they are of :

    i. Agree to practice two effective methods of from the time of signing of the form through three months after the last dose of the study drug, AND ii. Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or iii. Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)

  10. Male patients, even if surgically sterilized (i.e., status postvasectomy), must agree to one of the following:

    1. Practice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose, OR
    2. Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
    3. Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
  11. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment:

    1. Adoptive T-cell therapy (e.g., CAR T-cell therapy) at any time prior to enrollment.
    2. Bispecific antibody, or approved, irrespective of its target, at any time prior to enrollment.
    3. Use of talquetamab prior to enrollment.
    4. Any therapy targeting BCMA or GPRC5D, including but not limited to antibody-drug conjugates and/or monoclonal antibodies.
    5. Prior stem cell transplant at any time.
    6. Autologous stem cell transplant within 2 months of date of enrollment.
    7. High-dose cytotoxic chemotherapy (e.g., DCEP, KD-PACE, D-PACE) within 28 days of the enrollment date.
    8. Cytotoxic chemotherapy, such as cyclophosphamide, within 14 days of the enrollment date .
    9. Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.
    10. A cumulative dexamethasone dose of ≥ 100 mg within 14 days of the enrollment date .
    11. Radiation therapy within 7 days of the enrollment date.
  2. No ongoing Grade ≥ 3 non-hematological adverse events from prior therapy.
  3. Active central nervous system (CNS) involvement.
  4. Have plasma cell leukemia (PCL).
  5. Have unmeasurable disease (oligosecretory or non-secretory myeloma).
  6. Have concomitant AL amyloidosis.
  7. Patients with severe cardiac disease.

    1. Active heart disease with class III or IV congestive heart failure.
    2. History of myocardial infarction, unstable angina, placement of drug-eluting or metallic stent, coronary artery bypass graft in the last ≤ 6 months.
    3. ≤ 40% on transthoracic echocardiography.
    4. Severe non-ischemic cardiomyopathy.
  8. Patients with pulmonary dysfunction requiring continuous supplemental oxygen ≥ 2L/minute.
  9. Any serious medical condition such as:

    1. Disabling neurological or psychiatric conditions, including altered mental status, dementia, or any condition that could preclude the use of high-dose and/or accurate assessment of neurotoxicity.
    2. Any condition that could impair the ability of the subject to receive any of the study drugs.
  10. Infections:

    1. No new uncontrolled bacterial, viral or fungal infections.
    2. -positive patients on combination antiretroviral therapy are not eligible.
  11. Pregnant women are excluded from this study because talquetamab and cilta-cel have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with talquetamab, breastfeeding should be discontinued if the mother is treated with talquetamab.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Talquetamab and Ciltacabtagene autoleucel

    Participants with relapsed and/or refractory multiple myeloma (RRMM) will be administered talquetamab as a bridging therapy during CAR T-cell manufacturing and then receive Ciltacabtagene autoleucel CAR T-cell infusion after which they will be followed up to six months.

    Drug: Talquetamab · Drug: Ciltacabtagene Autoleucel

Interventions

06

What researchers measure

Primary outcomes

  1. The number of subjects without serious adverse events following Ciltacabtagene Autoleucel infusion through Day +30.

    SAEs will be assessed using the NCI CTCAE v5.0 during bridging therapy and for 30 days following infusion. Immune-mediated toxicities will be graded and assessed using the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading systems. SAEs that meet the definition of the primary endpoint analysis will include: 1. Any Grade 5 AE. 2. Any Grade ≥ 4 non-hematological treatment-related AE. 3. Cytokine release syndrome (Grade ≥ 3), immune-cell effector associated neurotoxicity syndrome (Grade ≥ 3) or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) of any grade.

    Time frame: Day+30 post Ciltacabtagene Autoleucel infusion

07

Study locations

1 of 1 sites recruiting
  • Froedtert & the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Othman Akhtar, MBBS · Contactoakhtar@mcw.edu · 414-805-4600
    • Othman Akhtar, MBBS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

Of 201 non-industry phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 18 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093554
Responsible party
Othman S Akhtar, MBBS (Assistant Professor, Medical College of Wisconsin) — Principal investigator
First posted
Jul 30, 2025
Start date
Dec 2, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jan 5, 2026

Study contacts

Medical College of Wisconsin Cancer Center Clinical Trials Office
Contact
cccto@mcw.edu
866-680-0505 ext. 8900
Othman Akhtar, MBBS
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Talquetamab · Ciltacabtagene autoleucel

Start the discussion